Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Relief therapeutics  /  Relief therapeutics Holding

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 1,215 17 apr 2024 16:15
  • -0,045 (-3,57%) Dagrange 1,215 - 1,230
  • 2.996 Gem. (3M) 15K

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 178 179 180 181 182 ... 456 »» | Laatste | Omlaag ↓
  1. [verwijderd] 16 oktober 2020 13:06
    quote:

    MisterBlues schreef op 16 oktober 2020 12:29:

    [...]

    Ik verwacht dat het middel wel anti-virale eigenschappen heeft voor longcellen. Vandaar de redelijk resultaten bij COPD en Covid-19 onderzoeken. Zonder Hexa stelt het echter niets voor.
    Dat denk ik dus ook alleen niet genoeg om een flinke virale infectie te stoppen.
  3. RodgerRodger 16 oktober 2020 13:51
    Check out the companies making headlines before the bell:

    Pfizer, BioNTech – Pfizer Chairman and CEO Albert Bourla said the vaccine candidate under development by the two drug makers could be ready for an Emergency Use Authorization application by late November. Separately, Pfizer and BioNTech are scaling up manufacturing capability for their experimental coronavirus vaccine, according to BioNTech CEO Ugur Sahin. Both companies have said they will be able to deliver the doses they’ve already agreed to provide to governments around the world, but Sahin said there will be a “struggle” to provide it more widely. Pfizer shares added 2.9% in premarket trading as of 7:30 a.m. ET.
  7. Bert-Jan 16 oktober 2020 16:10
    quote:

    Kleintje66 schreef op 16 oktober 2020 16:02:

    Volume nu ook veel hoger.
    Of zou er toch meer aan de hand zijn dan alleen FOMO? De afgelopen weken werd de koers super strak gehouden tussen een bepaalde (kleine) bandbreedte. Nu lijkt de koers ineens veel vrijer te bewegen zonder echt enorme volumes.
  9. [verwijderd] 16 oktober 2020 16:50
    quote:

    Bert-Jan schreef op 16 oktober 2020 16:10:

    [...]

    Of zou er toch meer aan de hand zijn dan alleen FOMO? De afgelopen weken werd de koers super strak gehouden tussen een bepaalde (kleine) bandbreedte. Nu lijkt de koers ineens veel vrijer te bewegen zonder echt enorme volumes.
    Tussen 0,40 en 0,60 vind ik vrij normaal in deze fase, het is dan net hoe de stemming is.
  11. forum rang 5 MisterBlues 16 oktober 2020 17:43
    Fijn weekend. Er komt echt pas wat eind oktober, namelijk DSMC, dan in november FDA.

    Relief in een notendop:

    Today is Friday the 16.October 2020 and I would like to remind you of the following:
    We hold the patent on RLF100 and the process for its synthesis. - We show the best results of any Covid drug I have ever seen. - We block the virus from attaching to host cells in the lung AND... we prevent the cytokine storm AND... reduce inflammation! - We have already been approved by the FDA as safe. - Our intravenous RLF100 was submitted to the EUA on 17.9. - pending FDA approval. - Our clinical studies with RLF100 have reached the preliminary 102 patients on September 30th - awaiting the results. - Our clinical trial for the RLF100 treatment inhaler has been designed, submitted and is expected to be completed later this year. - Our clinical trial for the RLF100 PREVENTATIVE Inhaler has been designed, submitted and is expected to be completed next year. - We are promising for lung applications other than Covid, which also need to be investigated and tested separately. - We signed a collaboration agreement with the Institute of Arthritis and Infectious Diseases of the NIH to test RLF-100 against the influenza virus and other viruses that attack the lung. - We signed a contract with Bachem Americas to manufacture a drug substance for 1 million patients. - We signed a contract with Nephron Pharma to produce enough RLF100 for 1 million patients. - We signed a contract with the largest supplier of inhaled sterile drugs in the United States to deliver RLF-100 overnight to any U.S. hospital. - In Israel, we have received the protocol for Accompanying Care, and we are in the process of deciding how to implement this protocol. - NeuroRX's CEO, Dr. Javitt, is in the top 1% of the cited scientists worldwide, has successfully guided 7 drugs through the FDA process and has held key leadership positions under Presidents Clinton, Bush Jr., Bush Sr. and Reagan. - Robert Bestoff, Chief of Operations of NeuroRX, spent his career with Lilly & Pfizer. At Pfizer, he led the entire neuroscience and pain division and was responsible for $10 billion of their drugs. - NeuroRX's manufacturing coordinator, Rich Siegel, is the former head of Johnson & Johnson's drug portfolio. - Relief has just appointed industry veteran Jack Weinstein as CFO AND retained former CFO Jeremy Meinen as Principal Finance and Accounting Officer. - Doctor (and Congressman) Andy Harris is 1 of 3 experts on the Data Monitoring Committee. Our team is of the highest caliber. Our team is focused. We make steady, precise progress. When it's time to "go"... the world will know!
  12. [verwijderd] 16 oktober 2020 18:41
    Ik vond dit wel een goeie samenvatting gepost op Yahoo:

    Rinaldo5 hours ago
    Today is Friday the 16.October 2020 and I would like to remind you of the following:
    We hold the patent on RLF100 and the process for its synthesis. - We show the best results of any Covid drug I have ever seen. - We block the virus from attaching to host cells in the lung AND... we prevent the cytokine storm AND... reduce inflammation! - We have already been approved by the FDA as safe. - Our intravenous RLF100 was submitted to the EUA on 17.9. - pending FDA approval. - Our clinical studies with RLF100 have reached the preliminary 102 patients on September 30th - awaiting the results. - Our clinical trial for the RLF100 treatment inhaler has been designed, submitted and is expected to be completed later this year. - Our clinical trial for the RLF100 PREVENTATIVE Inhaler has been designed, submitted and is expected to be completed next year. - We are promising for lung applications other than Covid, which also need to be investigated and tested separately. - We signed a collaboration agreement with the Institute of Arthritis and Infectious Diseases of the NIH to test RLF-100 against the influenza virus and other viruses that attack the lung. - We signed a contract with Bachem Americas to manufacture a drug substance for 1 million patients. - We signed a contract with Nephron Pharma to produce enough RLF100 for 1 million patients. - We signed a contract with the largest supplier of inhaled sterile drugs in the United States to deliver RLF-100 overnight to any U.S. hospital. - In Israel, we have received the protocol for Accompanying Care, and we are in the process of deciding how to implement this protocol. - NeuroRX's CEO, Dr. Javitt, is in the top 1% of the cited scientists worldwide, has successfully guided 7 drugs through the FDA process and has held key leadership positions under Presidents Clinton, Bush Jr., Bush Sr. and Reagan. - Robert Bestoff, Chief of Operations of NeuroRX, spent his career with Lilly & Pfizer. At Pfizer, he led the entire neuroscience and pain division and was responsible for $10 billion of their drugs. - NeuroRX's manufacturing coordinator, Rich Siegel, is the former head of Johnson & Johnson's drug portfolio. - Relief has just appointed industry veteran Jack Weinstein as CFO AND retained former CFO Jeremy Meinen as Principal Finance and Accounting Officer. - Doctor (and Congressman) Andy Harris is 1 of 3 experts on the Data Monitoring Committee. Our team is of the highest caliber. Our team is focused. We make steady, precise progress. When it's time to "go"... the world will know!
  15. forum rang 5 MisterBlues 17 oktober 2020 11:24
    Voor de liefhebbers (en handig om deze link te hebben voor later).

    The FDA has more than 50 regulatory pathways available to companies hoping to get a new drug or biologic approved. Here are the 22 that are most likely to be used to help bring new COVID-19 products to patients.

    Alexander Gaffney is the author of this piece (agaffney@agencyiq.com)

    agencyiq.com/the-twenty-two-regulator...
9.103 Posts
Pagina: «« 1 ... 178 179 180 181 182 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!